FDA Funding Proposal Includes Cross-Cutting Oncology Focus, Disappoints Budget Advocates
This article was originally published in The Gray Sheet
Executive Summary
President Obama sent Congress a budget that would increase FDA's coffers by $360 million, but mostly from user fees. Advocacy groups say the proposal is insufficient considering the agency's growing responsibilities. Included in the request is money for a new Oncology Center of Excellence that would take a cross-agency effort to support development of combination therapies for cancer.
You may also be interested in...
FDA Reorganization Advocates Seek Senate Boost For Disease-Oriented Structure
Friends of Cancer Research proposes realignment of FDA to be organized more around disease areas and less around the distinctions between drugs, devices and biologics. The idea has generated some support from former commissioners and current officials, while others warn of unintended consequences.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.